Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib and Ramucirumab in EGFR Exon 20 Mutant Advanced NSCLC
NCT05045404Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Jun 2021; status: withdrawn.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05045404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05045404.